InvestSMART

Creso Pharma Limited (ASX: CPH) - Announcements

- Current share price for CPH : $0.009

ASX company news and announcements for Creso Pharma Limited (CPH) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Creso Pharma Limited (CPH) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Creso Pharma Limited (CPH), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Creso Pharma Limited (CPH)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- CPH Establishes Edible Cannabis Product R&D Centre 30 Oct 2018 8:35AM $0.425 $0.009 fallen by 97.88%
- Appendix 3B - Release from Escrow 22 Oct 2018 11:22AM $0.525 $0.009 fallen by 98.29%
- Change of Company Secretary 19 Oct 2018 5:59PM $0.590 $0.009 fallen by 98.47%
- Cleansing Statement & Appendix 3B - Exercise of Options 18 Oct 2018 12:17PM $0.590 $0.009 fallen by 98.47%
- Creso welcomes legalisation of recreational cannabis, Canada 17 Oct 2018 9:29AM $0.555 $0.009 fallen by 98.38%
- Results of Meeting 16 Oct 2018 1:51PM $0.525 $0.009 fallen by 98.29%
- Appendix 3B 11 Oct 2018 4:48PM $0.515 $0.009 fallen by 98.25%
- Old Boy Mary Jane Beer Launch in London, Berlin 9 Oct 2018 9:48AM $0.545 $0.009 fallen by 98.35%
- Securities to be released from escrow 8 Oct 2018 5:49PM $0.545 $0.009 fallen by 98.35%
- Licence application accepted & Construction Finance Loan 8 Oct 2018 8:27AM $0.555 $0.009 fallen by 98.38%
- Change of Registry Address: Automic P/L - Sydney Office 28 Sep 2018 12:27PM $0.560 $0.009 fallen by 98.39%
- FNN Interview with Chief Operating Officer 18 Sep 2018 8:23AM $0.565 $0.009 fallen by 98.41%
- Appendix 3B - Quotation of Options 12 Sep 2018 6:22PM $0.585 $0.009 fallen by 98.46%
- Appendix 3B - Options Entitlement Issue Shortfall 11 Sep 2018 6:02PM $0.575 $0.009 fallen by 98.43%
- Update on Colombian Acquisition & Notice of General Meeting 11 Sep 2018 8:47AM $0.565 $0.009 fallen by 98.41%
- Creso Pharma Lifestyle Portfolio Update 5 Sep 2018 8:20AM $0.605 $0.009 fallen by 98.51%
- Quotation of Entitlement Issue Options 31 Aug 2018 8:10AM $0.615 $0.009 fallen by 98.54%
- Half Yearly Report and Accounts 28 Aug 2018 6:59PM $0.595 $0.009 fallen by 98.49%
- Appendix 3B - Quotation of Options 28 Aug 2018 1:41PM $0.580 $0.009 fallen by 98.45%
- Appendix 3Y x 4 - Options Entitlement Issue 27 Aug 2018 2:04PM $0.610 $0.009 fallen by 98.52%
- Appendix 3B 21 Aug 2018 12:13PM $0.650 $0.009 fallen by 98.62%
- UK commercialisation of cannaQIX with Pharmacare 21 Aug 2018 8:23AM $0.555 $0.009 fallen by 98.38%
- Entitlement Issue Shortfall Notice 17 Aug 2018 5:50PM $0.555 $0.009 fallen by 98.38%
- Commercial agreement for cannaQIX in Austria & East Europe 14 Aug 2018 8:11AM $0.515 $0.009 fallen by 98.25%
- Dispatch of Entitlement Issue Prospectus 3 Aug 2018 2:00PM $0.630 $0.009 fallen by 98.57%

676 - 700 of 891 results

Page 28 of 36

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.